← Eichor
Study identifier: NCT04915183 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Condition: Hearing Loss · Head and Neck Cancer  ·  Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD)

PhasePhase 2
Planned participants224
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss. Objective: To find out if atorvastatin reduces hearing loss in people treated with cisplatin and radiation. Eligibility: People ages 18 and older with squamous cell carcinoma of the head and neck who will undergo treatment with cisplatin-based chemotherapy and radiation Design: Participants will be screened with their medical records. Participants currently taking a cholesterol-lowering statin medication are invited to participate in the observational arm of the study. Those not taking such a medication are invited to participate in the interventional arm of the study. All participants will have 3 study visits for the purpose of evaluating hearing. One before starting cisplatin treatment, one within 3 months of completing cancer treatment, and one within 2 years of completing cancer treatment. They will have tympanograms. A small flexible tip will be placed in the ear canal. A puff of air will be delivered to assess mobility of the ear drum. They will have hearing tests. They will wear headphones. They will listen to tones that vary in loudness. They will be asked to indicate when they hear a sound. They will complete 3 questionnaires at the time of each hearing test. Participants will have 2 visits for blood tests. These will occur upon …

This description comes directly from the study's public registry record.

Talk to the study team

Katharine A Fernandez, Au.D.  ·  (240) 215-7152  ·  katharine.fernandez@nih.gov

Lisa L Cunningham, Ph.D.  ·  (301) 443-2766  ·  cunninghamll@mail.nih.gov

Always discuss trial participation with your own doctor first.

Locations (5)

Winship Cancer Institute at Emory UniversityAtlanta, Georgia, United StatesRecruiting
University of Maryland Medical CenterBaltimore, Maryland, United StatesRecruiting
National Institutes of Health Clinical CenterBethesda, Maryland, United StatesRecruiting
Wilmot Cancer Institute at the University of Rochester Medical Center in New YorRochester, New York, United StatesRecruiting
Inova Schar Cancer CenterFairfax, Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04915183